ReviewTherapeutic advances in chronic disease2018
Management of functional dyspepsia: state of the art and emerging therapies.
Review in Therapeutic advances in chronic disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Physical-based therapy for the treatment of functional dyspepsia: a systematic review.Clinical journal of gastroenterology · 2026Pooled it
- Randomized trial of the effect of esomeprazole on functional dyspepsia during Ramadan fasting.Scientific reports · 2025Trial
- Functional dyspepsia and risk of Barrett's esophagus and dysplasia: A propensity-matched multicenter retrospective cohort study.World journal of methodology · 2026Article
- What goes down may come up: regurgitative behaviors and their underlying gut-brain axes-insights from genetic models and related pathologies.Journal of comparative physiology. A, Neuroethology, sensory, neural, and behavioral physiology · 2026Review
- Age- and Risk-Based Stratification in Dyspepsia: Redefining Endoscopic Thresholds for Clinically Significant and Malignant Findings.Clinics and practice · 2025Article
- Functional dyspepsia: from human to dog, a retrospective study of 29 cases illustrating a complex entity.BMC veterinary research · 2025Article
- Efficacy of Acotiamide in Pediatric Patients with Functional Dyspepsia.Pediatric gastroenterology, hepatology & nutrition · 2025Article
- Comparative Assessment of the Anti-Cells · 2024Article
- Intestinal Effects of Filtered Alkalinized Water in Lean and Obese Zucker Rats.Microorganisms · 2024Article
- Management of dyspepsia and Helicobacter pylori infection: the 2022 Indonesian Consensus Report.Gut pathogens · 2023Review
- Pharmacological Treatment of Functional Dyspepsia: An Old Story Revisited or a New Story to Be Told? A Clinical Review.GE Portuguese journal of gastroenterology · 2023Review
- Comparing the efficacy of duloxetine and nortriptyline in alleviating the symptoms of functional dyspepsia - a randomized clinical trial.Frontiers in psychiatry · 2023Article
- Complementary and alternative medicine for functional dyspepsia: An Asian perspective.Medicine · 2022Article
- Efficacy of acotiamide on postprandial distress syndrome and epigastric pain syndrome depending on the estimated gastric acid secretion level.Journal of neurogastroenterology and motility · 2022Article
- A study of the therapeutic mechanism of Jakyakgamcho-Tang about functional dyspepsia through network pharmacology research.International journal of medical sciences · 2022Article
- Neural Responses of Acupuncture for Treating Functional Dyspepsia: An fMRI Study.Frontiers in neuroscience · 2022Article
- The therapy of functional dyspepsia: an update.Medicine and pharmacy reports · 2021Article
- Efficacy and Safety of DWJ1252 Compared With Gasmotin in the Treatment of Functional Dyspepsia: A Multicenter, Randomized, Double-blind, Active-controlled Study.Journal of neurogastroenterology and motility · 2021Article
- Potential Mechanisms of Acupuncture for Functional Dyspepsia Based on Pathophysiology.Frontiers in neuroscience · 2021Review
- Clinical efficacy ofAmerican journal of translational research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with functional dyspepsia, defined in the 2016 Rome IV criteria as bothersome clinical dyspepsia symptoms, experience markedly reduced quality of life. Several etiologies have been associated with the disorder. In the Rome IV criteria, the brain-gut axis was acknowledged as an important factor in the etiology of functional gastrointestinal (GI) disorders. The distinct subgroups of functional dyspepsia, epigastric pain syndrome (EPS) and postprandial distress syndrome (PDS), are treated differently: acid secretion inhibitors are recommended with patients with EPS, whereas prokinetic drugs as mosapride and acotiamide are recommended for patients with PDS. A previous study has reported that proton pump inhibitors (PPIs) and H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.